Centessa Pharmaceuticals (CNTA) Depreciation & Amortization (CF) (2021 - 2026)
Centessa Pharmaceuticals (CNTA) reported Depreciation & Amortization (CF) of $239000.0 for Q1 2026, up 10.14% year-over-year from $217000.0 in Q1 2025, and down 0.83% on a QoQ basis from $241000.0 in Q4 2025.
Centessa Pharmaceuticals (CNTA) has 6 years of Depreciation & Amortization (CF) data on file, last reported at $239000.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 10.14% year-over-year to $239000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $943000.0 (up 2.61% YoY) and the FY2025 annual result came in at $921000.0, down 2.23% from the prior year.
- Depreciation & Amortization (CF) fell to $239000.0 in Q1 2026 per CNTA's latest filing, from $241000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $246000.0 in Q4 2023 and bottomed at $28000.0 in Q1 2022.
- The 5-year median for Depreciation & Amortization (CF) is $236000.0 (2024), against an average of $179000.0.
- The widest annual swing landed in 2022, when Depreciation & Amortization (CF) surged 1300.0%; it then retreated 9.58% in 2025.
- Tracing CNTA's Depreciation & Amortization (CF) over 5 years: stood at $36000.0 in 2022, then jumped by 583.33% to $246000.0 in 2023, then declined by 6.5% to $230000.0 in 2024, then advanced by 4.78% to $241000.0 in 2025, then fell by 0.83% to $239000.0 in 2026.
- Per Business Quant, the three latest CNTA Depreciation & Amortization (CF) figures stand at $239000.0 (Q1 2026), $241000.0 (Q4 2025), and $237000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1,395.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 55.90 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 123.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 13.55 Mn |
| 10 | Centessa Pharmaceuticals | 6.12 Bn | 6.12 Bn | - | 239,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 239,000.00 |
| Mar 31, 2026 | 239,000.00 |
| Dec 31, 2025 | 241,000.00 |
| Dec 31, 2025 | 241,000.00 |
| Sep 30, 2025 | 237,000.00 |
| Sep 30, 2025 | 237,000.00 |
| Jun 30, 2025 | 226,000.00 |
| Jun 30, 2025 | 226,000.00 |
| Mar 31, 2025 | 217,000.00 |
| Mar 31, 2025 | 217,000.00 |
| Dec 31, 2024 | 230,000.00 |
| Dec 31, 2024 | 230,000.00 |
| Sep 30, 2024 | 236,000.00 |
| Sep 30, 2024 | 236,000.00 |
| Jun 30, 2024 | 236,000.00 |
| Jun 30, 2024 | 236,000.00 |
| Mar 31, 2024 | 240,000.00 |
| Mar 31, 2024 | 240,000.00 |
| Dec 31, 2023 | 246,000.00 |
| Dec 31, 2023 | 246,000.00 |
| Sep 30, 2023 | 238,000.00 |
| Sep 30, 2023 | 238,000.00 |
| Jun 30, 2023 | 237,000.00 |
| Jun 30, 2023 | 237,000.00 |
| Mar 31, 2023 | 89,000.00 |
| Mar 31, 2023 | 89,000.00 |
| Dec 31, 2022 | 36,000.00 |
| Dec 31, 2022 | 36,000.00 |
| Sep 30, 2022 | 35,000.00 |
| Sep 30, 2022 | 35,000.00 |
| Jun 30, 2022 | 32,000.00 |
| Jun 30, 2022 | 32,000.00 |
| Mar 31, 2022 | 28,000.00 |
| Mar 31, 2022 | 28,000.00 |
| Dec 31, 2021 | 12,000.00 |
| Dec 31, 2021 | 12,000.00 |
| Sep 30, 2021 | 13,000.00 |
| Sep 30, 2021 | 13,000.00 |
| Jun 30, 2021 | 7,000.00 |
| Jun 30, 2021 | 7,000.00 |
| Mar 31, 2021 | 2,000.00 |
| Mar 31, 2021 | 2,000.00 |